AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16003515 — intervention group
Group type: EXPERIMENTAL
Intervention: carteolol 2% LA once daily for 2 months
Number of subjects: 23
Study 16003515 — intervention group
Group type: COMPARATOR
Intervention: carteolol 2% regular twice daily for 2 months
Number of subjects: 23
Study 12501943 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar taping
Number of subjects: 15
Study 10599713 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 and P replacement (2.30 mg/kg x day E2 and 21.20 mg/kg x day P, iv)
Number of subjects: 30
Study 10599713 — intervention group
Group type: COMPARATOR
Intervention: No replacement
Number of subjects: 30
Study 8605790 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1 mg/kg followed by an infusion of 1.5 mg/kg/hr for 24 hrs)
Number of subjects: 16
Study 8605790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8605790 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 16
Study 1826961 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + SR 2508
Number of subjects: 242
Study 1826961 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 242
Study 6128019 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine (10 mg sustained release)
Number of subjects: 0
Study 6128019 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg)
Number of subjects: 0
Study 6128019 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg)
Number of subjects: 0
Study 6128019 — intervention group
Group type: COMPARATOR
Intervention: Control (no antihistamine)
Number of subjects: 0
Study 31046620 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention for sit-to-stand movement
Number of subjects: 91
Study 31046620 — intervention group
Group type: COMPARATOR
Intervention: Baseline factors in always-able subgroup
Number of subjects: 91
Study 28922099 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, Lactobacillus fermentum; 2 × 10^9 colony‐forming units/g each; n = 20)
Number of subjects: 40
Study 28922099 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 40
Study 25023068 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Number of subjects: 34
Study 25023068 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 34
Study 24705469 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 39
Study 24705469 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 39
Study 20392523 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermis
Number of subjects: 42
Study 20392523 — intervention group
Group type: COMPARATOR
Intervention: Temporalis fascia
Number of subjects: 42
Study 19707782 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowing in water
Number of subjects: 8
Study 18005415 — intervention group
Group type: EXPERIMENTAL
Intervention: Confrontational counselling delivered by a respiratory nurse combined with nortriptyline for smoking cessation
Number of subjects: 0
Study 18005415 — intervention group
Group type: COMPARATOR
Intervention: Health education and promotion delivered by a respiratory nurse combined with nortriptyline for smoking cessation
Number of subjects: 0
Study 18005415 — intervention group
Group type: COMPARATOR
Intervention: Care as usual delivered by the GP
Number of subjects: 0
Study 15572850 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zafirlukast (40 mg/day) in addition to budesonide for 6 weeks
Number of subjects: 21
Study 15572850 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to budesonide for 6 weeks
Number of subjects: 21
Study 11359426 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus red mite (Panonychus citri)
Number of subjects: 7254
Study 11359426 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive skin responses to the citrus red mite
Number of subjects: 7254
Study 11359426 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA inhibition tests
Number of subjects: 7254
Study 8995587 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin treatment
Number of subjects: 41
Study 8432154 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 88
Study 8432154 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 88
Study 3434006 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate (2.0 mg/day)
Number of subjects: 52
Study 3434006 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (5.0 mg/day)
Number of subjects: 52
Study 3434006 — intervention group
Group type: COMPARATOR
Intervention: Control (before treatment)
Number of subjects: 52
Study 29730623 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Nurse Partnership (FNP) home visiting programme added to usual care
Number of subjects: 161
Study 29730623 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 161
Study 26724456 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascularized bone grafting fixed by biodegradable magnesium screws
Number of subjects: 48
Study 26724456 — intervention group
Group type: COMPARATOR
Intervention: Vascularized bone grafting without fixation (Control)
Number of subjects: 48
Study 24816936 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose unenhanced ungated chest CT for AVC measurement
Number of subjects: 578
Study 24816936 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose unenhanced ungated chest CT for MC measurement
Number of subjects: 578
Study 22116011 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial Incentive Coercion Assessment (FICA) questionnaire
Number of subjects: 266
Study 22116011 — intervention group
Group type: EXPERIMENTAL
Intervention: FICA results
Number of subjects: 266
Study 22116011 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial assessment of responses on the FICA
Number of subjects: 266
Study 20060578 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 1800
Study 20060578 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent
Number of subjects: 1800
Study 17604556 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (N=4)
Number of subjects: 7
Study 17604556 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (N=3)
Number of subjects: 7
Study 16110738 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in the GISSA intervention study
Number of subjects: 1269
Study 16110738 — intervention group
Group type: COMPARATOR
Intervention: Non-participants who refused, did not respond, or withdrew
Number of subjects: 1269
Study 12087908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment program (synchronous plasmapheresis, large-dose methotrexate and methylprednisolone)
Number of subjects: 45
Study 12087908 — intervention group
Group type: COMPARATOR
Intervention: Pulse therapy with methylprednisolone (3 g) and methotrexate (200 mg)
Number of subjects: 45
Study 10195618 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypsin-modified inactivated poliovirus vaccine (TryIPV)
Number of subjects: 0
Study 10195618 — intervention group
Group type: COMPARATOR
Intervention: Enhanced potency inactivated poliovirus vaccine (E-IPV)
Number of subjects: 0
Study 7780243 — intervention group
Group type: EXPERIMENTAL
Intervention: High cholesterol formula (30 mg/dl cholesterol)
Number of subjects: 44
Study 7780243 — intervention group
Group type: COMPARATOR
Intervention: Breast milk (mean cholesterol content 15.3 mg/dl)
Number of subjects: 44
Study 7780243 — intervention group
Group type: COMPARATOR
Intervention: Standard preterm formula (cholesterol content 5.5 mg/dl)
Number of subjects: 44
Study 7780243 — intervention group
Group type: COMPARATOR
Intervention: Low cholesterol formula
Number of subjects: 44
Study 2141104 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol, 2.5 mg
Number of subjects: 31
Study 2141104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium, 0.250 mg
Number of subjects: 31
Study 2141104 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol + Ipratropium
Number of subjects: 31
Study 2141104 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 31
Study 637066 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery
Number of subjects: 33
Study 637066 — intervention group
Group type: EXPERIMENTAL
Intervention: Rote repetition
Number of subjects: 33
Study 637066 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study 30945991 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight training combined with pelvic floor muscle training (moderate intensity, twice a week for 12 weeks)
Number of subjects: 26
Study 30945991 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training alone
Number of subjects: 26
Study 27417272 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral nutrition intervention
Number of subjects: 136
Study 25891042 — intervention group
Group type: EXPERIMENTAL
Intervention: Real condition (food addiction is real)
Number of subjects: 60
Study 25891042 — intervention group
Group type: COMPARATOR
Intervention: Myth condition (food addiction is a myth)
Number of subjects: 60
Study 23263396 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquacel Ag dressing
Number of subjects: 92
Study 23263396 — intervention group
Group type: COMPARATOR
Intervention: Iodoform dressing
Number of subjects: 92
Study 21368086 — intervention group
Group type: COMPARATOR
Intervention: Alcoholics (during rest)
Number of subjects: 0
Study 21368086 — intervention group
Group type: COMPARATOR
Intervention: Alcoholics (during task)
Number of subjects: 0
Study 21368086 — intervention group
Group type: COMPARATOR
Intervention: Controls (during rest)
Number of subjects: 0
Study 21368086 — intervention group
Group type: COMPARATOR
Intervention: Controls (during task)
Number of subjects: 0
Study 19186028 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis session with specific suggestions to increase salivation, recorded on a CD, listened to twice a day for one month
Number of subjects: 12
Study 19186028 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis session
Number of subjects: 12
Study 19186028 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis CD listening frequency
Number of subjects: 12
Study 16255784 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomass fuel use (wood)
Number of subjects: 369
Study 16255784 — intervention group
Group type: COMPARATOR
Intervention: LPG (Liquefied Petroleum Gas) use
Number of subjects: 369
Study 12048134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day for 8 weeks
Number of subjects: 25
Study 12048134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg/day for up to 104 weeks
Number of subjects: 25
Study 12048134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 25
Study 10368193 — intervention group
Group type: EXPERIMENTAL
Intervention: Prelubricated, hydrophilic PVC catheter
Number of subjects: 32
Study 10368193 — intervention group
Group type: COMPARATOR
Intervention: Non-hydrophilic PVC catheter
Number of subjects: 32
Study 7744936 — intervention group
Group type: EXPERIMENTAL
Intervention: Thorough saline lavage of the femoral canal
Number of subjects: 24
Study 7744936 — intervention group
Group type: COMPARATOR
Intervention: Minimal saline lavage of the femoral canal
Number of subjects: 24
Study 2304406 — intervention group
Group type: EXPERIMENTAL
Intervention: Light weight belt (LB)
Number of subjects: 6
Study 2304406 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy weight belt (HB)
Number of subjects: 6
Study 2304406 — intervention group
Group type: COMPARATOR
Intervention: No belt (NB)
Number of subjects: 6
Study 6118757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6118757 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 20
Study 31908865 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach training and the PACK guide
Number of subjects: 6666
Study 31908865 — intervention group
Group type: COMPARATOR
Intervention: Control group (only the PACK guide)
Number of subjects: 6666
Study 29130440 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based brief intervention involving emotionally evocative photographs and discussions with a healthcare provider.
Number of subjects: 87
Study 29130440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 87
Study 29130440 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based brief intervention.
Number of subjects: 87
Study 25688120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense temozolomide
Number of subjects: 0
Study 25688120 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose temozolomide
Number of subjects: 0
Study 25688120 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressed patients
Number of subjects: 0
Study 25688120 — intervention group
Group type: COMPARATOR
Intervention: Nonprogressors
Number of subjects: 0
Study 23603021 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the right angular gyrus (AG)
Number of subjects: 0
Study 23603021 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (identical electrode set-up without stimulation)
Number of subjects: 0
Study 23603021 — intervention group
Group type: COMPARATOR
Intervention: Control (no electrodes attached)
Number of subjects: 0
Study 21272986 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope(®)
Number of subjects: 45
Study 21272986 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 45
Study 19876936 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine extended release tablets with varying polymer contents
Number of subjects: 0
Study 19876936 — intervention group
Group type: COMPARATOR
Intervention: Fastest ER formulation (used as reference for UIR)
Number of subjects: 0
Study 17074337 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 40
Study 17074337 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (150 mg for 5 days)
Number of subjects: 40
Study 17074337 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy normal cycled women)
Number of subjects: 40
Study 15597184 — intervention group
Group type: EXPERIMENTAL
Intervention: Stream of three items belonging to the same category (e.g., letters or digits)
Number of subjects: 0
Study 15597184 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of an item from a different category in the target string
Number of subjects: 0
Study 15597184 — intervention group
Group type: COMPARATOR
Intervention: Theoretical accounts of attentional blink
Number of subjects: 0
Study 15597184 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary loss of control over the prevailing attentional set
Number of subjects: 0
Study 12188409 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting pelvic tilt exercise for 8 weeks during the third trimester
Number of subjects: 67
Study 10432138 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (600 microg)
Number of subjects: 0
Study 10432138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8534468 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐Anesthetic Discharge Scoring System (PADSS)
Number of subjects: 247
Study 8534468 — intervention group
Group type: COMPARATOR
Intervention: Clinical Discharge Criteria
Number of subjects: 247
Study 2151435 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide 300 mg t.i.d. for 10 days
Number of subjects: 10
Study 6988787 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance based on the infant's developmental status at each age
Number of subjects: 32
Study 6988787 — intervention group
Group type: COMPARATOR
Intervention: Customary care
Number of subjects: 32
Study 31046117 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based (CB) recruitment method
Number of subjects: 453
Study 31046117 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person hospital clinic (HC) recruitment method
Number of subjects: 453
Study 31046117 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic medical record (EMR) recruitment method
Number of subjects: 453
Study 31046117 — intervention group
Group type: EXPERIMENTAL
Intervention: Information sessions (CB approach)
Number of subjects: 453
Study 31046117 — intervention group
Group type: EXPERIMENTAL
Intervention: Flyers (CB approach)
Number of subjects: 453
Study 31046117 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recruitment yield
Number of subjects: 453
Study 31046117 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of recruiting and enrolling one participant
Number of subjects: 453
Study 30755249 — intervention group
Group type: EXPERIMENTAL
Intervention: PASTA pathway delivered by paramedics including structured pre-hospital information collection, prompted pre-notification, structured handover of information in hospital, and assistance with simple tasks during the initial hospital assessment.
Number of subjects: 1297
Study 30755249 — intervention group
Group type: COMPARATOR
Intervention: Standard stroke care according to national and local guidelines for the pre-hospital and hospital assessment of suspected stroke.
Number of subjects: 1297
Study 28280310 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-to-refill (LTR) reminder calls
Number of subjects: 735218
Study 25248358 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-restriction meal-replacement diet (CRMR)
Number of subjects: 143
Study 25248358 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-restriction diet with fish oil supplementation (CRF)
Number of subjects: 143
Study 25248358 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-restriction meal-replacement diet with fish oil supplementation (CRMRF)
Number of subjects: 143
Study 25248358 — intervention group
Group type: COMPARATOR
Intervention: Calorie-restriction diet (CR)
Number of subjects: 143
Study 25248358 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 143
Study 25151418 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented therapy (parent training, stimulant medication, and risperidone)
Number of subjects: 168
Study 25151418 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy (parent training, stimulant medication, and placebo)
Number of subjects: 168
Study 22376026 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate (CHX) oral swabbing four times/day
Number of subjects: 61
Study 22376026 — intervention group
Group type: COMPARATOR
Intervention: Saline oral swabbing four times/day
Number of subjects: 61
Study 19580706 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC 1 hour/thrice-a-day for 4 months (Group 2)
Number of subjects: 36
Study 19580706 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC 2 hours/once-a-day for 4 months (Group 3)
Number of subjects: 36
Study 19580706 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC 1 hour/thrice-a-day for 2 months (Group 4)
Number of subjects: 36
Study 19580706 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC 2 hours/once-a-day for 2 months (Group 5)
Number of subjects: 36
Study 19580706 — intervention group
Group type: COMPARATOR
Intervention: No IPC (Group 1)
Number of subjects: 36
Study 17263604 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave lithotripsy (SWL)
Number of subjects: 71
Study 17263604 — intervention group
Group type: COMPARATOR
Intervention: Ureteroscopy (URS)
Number of subjects: 71
Study 15631278 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 16 mg plus hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 409
Study 15631278 — intervention group
Group type: COMPARATOR
Intervention: Previous monotherapy (PM) plus hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 409
Study 11603446 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium infusion (6 mmol MgSO4 in 100 mL 0.9% NaCl solution, 25 mL/h) administered the day before surgery, just after cardiopulmonary bypass, and once daily for 4 days after surgery
Number of subjects: 200
Study 11603446 — intervention group
Group type: COMPARATOR
Intervention: Control group received 100 mL 0.9% NaCl solution (25 mL/h) at the same time points
Number of subjects: 200
Study 9673728 — intervention group
Group type: EXPERIMENTAL
Intervention: Costal cartilage allograft
Number of subjects: 353
Study 9673728 — intervention group
Group type: COMPARATOR
Intervention: Bone pate autograft
Number of subjects: 353
Study 7717809 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose free formula (AL‐110, Nestle Labs.)
Number of subjects: 52
Study 7717809 — intervention group
Group type: COMPARATOR
Intervention: Lactose formula
Number of subjects: 52
Study 2462660 — intervention group
Group type: EXPERIMENTAL
Intervention: QBC tube test
Number of subjects: 600
Study 2462660 — intervention group
Group type: COMPARATOR
Intervention: Thick blood smear
Number of subjects: 600
Study 4552445 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobials
Number of subjects: 100
Study 4552445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30103740 — intervention group
Group type: EXPERIMENTAL
Intervention: AlphaKit® QuickScreen
Number of subjects: 1044
Study 30103740 — intervention group
Group type: COMPARATOR
Intervention: Genotyping (gold standard)
Number of subjects: 1044
Study 26860430 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium goal (n=19)
Number of subjects: 96
Study 26860430 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult goal (n=19)
Number of subjects: 96
Study 26860430 — intervention group
Group type: COMPARATOR
Intervention: Easy goal (n=19)
Number of subjects: 96
Study 26860430 — intervention group
Group type: COMPARATOR
Intervention: Do-your-best goal (n=19)
Number of subjects: 96
Study 26860430 — intervention group
Group type: COMPARATOR
Intervention: No goal (n=20)
Number of subjects: 96
Study 26860430 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy, Medium, and Difficult goal groups
Number of subjects: 96
Study 24700332 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Education System (TES)
Number of subjects: 507
Study 24700332 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 507
Study 24700332 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Education System (TES) among patients with positive urine drug or breath alcohol screen at study entry (N=228)
Number of subjects: 507